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Vitamin D is absolutely essential for the
provision of a mechanically robust, min-
eralized bone collagen matrix. Whilst their
continues to be a debate over the pre-
cise role of this steroid in bone biol-
ogy it is unequivocal that active vitamin
D3 metabolites have direct effects on the
control of human osteoblast (hOB) func-
tion, matrix calcification and overall bone
metabolism. Indeed van de Peppel and van
Leeuwen identify many studies support-
ing a direct effect of the active vitamin
D3 metabolite, 1,25-dihydroxyvitamin D3
(1,25D), in hOBs. It is also clear that
these cells are receptive to 24,25D, and that
the responses observed are a consequence
of vitamin D receptor (VDR)-mediated
events. Of additional significance are
the reports describing cross-talk between
1,25D and other growth factors known
to influence hOB activity. These are espe-
cially important developments that will
help decipher the multiple networks which
interconnect with vitamin D in controlling
gene expression linked to the regula-
tion of cell growth, bone matrix syn-
thesis and mineralization. The identities
of these molecules in turn offer enticing
opportunities in developing novel strate-
gies to facilitate 1,25D enhanced bone
repair and/or regeneration where it might
be needed most, for example at sites of
fracture non-unions and at bone bioma-
terial surfaces to bolster their integration
into host tissue.
The cited growth factors known to
participate with 1,25D are wide ranging
and include local bone mediators, e.g.,
TGFbeta, the calciotropic hormone PTH
and Wnt signaling ligands. Collectively
these studies underpin the diversity of sig-
nal transduction networks that converge
on 1,25D in regulating hOB function.
There is however a surprising omission by
van de Peppel and van Leeuwen; the simple
bioactive glycerophospholipid, lysophos-
phatidic acid (LPA). This particular lipid
is one of only three reported growth fac-
tors known to synergistically co-operate
with 1,25D in promoting hOB matura-
tion; TGFbeta and EGF are the other
two agents. Approximately a decade ago
Mansell’s group (Gidley et al., 2006) dis-
covered that the ability of 1,25D to stim-
ulate hOB (MG63) alkaline phosphatase
(ALP) expression was a consequence of
signaling co-operation with serum-borne
LPA, as bound to the albumin fraction. In
the absence of serum 1,25D had, at best, a
trivial influence on ALP expression. Since
this initial finding several published works
have emerged describing the co-operative
effects of LPA and selected LPA recep-
tor agonists with 1,25D/24,25D on hOB
formation and maturation, not only in a
conventional tissue culture setting but in
association with titanium and hydroxya-
patite, two widely used bone biomaterials
(Blackburn and Mansell, 2012; Lancaster
et al., 2014).
It has been known for over two decades
that the bulk of serum LPA, the most
abundant growth factor in serum, is sta-
bly bound to the albumin fraction. Indeed
an explanation as to why serum starved
fibroblasts accrued enormous quantities
of F-actin stress fibers in response to
serum was attributed to albumin bound
LPA (Ridley and Hall, 1992). Similarly
Tigyi and colleagues discovered that the
serum-borne component responsible for
evoking membrane currents in Xenopus
oocytes and neurite retraction in PC12
pheochromocytoma cells was LPA teth-
ered to albumin (Tigyi, 2010). Given that
1,25D co-operates with LPA in promoting
hOB maturation this raises a poten-
tially important point pertaining to stud-
ies investigating the in vitro effects of
1,25D, either alone, or in combination
with selected agents. It is likely that such
studies are inadvertently reporting on
signaling cross-talk with LPA associated
with whole serum or native, serum albu-
min. Greater attention should therefore
be placed in defining the culture condi-
tions when examining the influence of
1,25D on hOBs; essentially fatty acid-free
albumin(s) or charcoal stripped sera are
obvious alternatives to eliminate signaling
interference from LPA.
The ability of 1,25D to act in concert
with LPA in promoting ALP expression
is an exciting development in hOB biol-
ogy. Although it is generally agreed that
1,25D influences the expression of hOB
genes synonymous with their transition
to a more mature phenotype, the role of
1,25D in the context of ALP expression
has yet to be more clearly defined. Despite
the clear connection between 1,25D and
bone mineralization and the vital role of
ALP in this process, ALP, unlike osteo-
calcin for example, is not identified as
a 1,25D responsive gene. This is a par-
ticularly intriguing paradox. Whilst there
is evidence of a vitamin D response ele-
ment like-motif in the promoter region
of the human ALP gene it is reportedly
non-functional. It has been proposed that
a role of 1,25D in ALP expression is a
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consequence of enhanced mRNA stability
rather than direct transcriptional control
(Orimo and Shimada, 2006; Orimo, 2010).
In this regard 1,25D amplifies protein
expression by extending the life of the
ALP transcript. It is conceivable therefore
that the synergistic increases observed for
hOB ALP consequent to co-stimulation
with 1,25D and LPA, is an enhancement,
of an otherwise modest, LPA-induced
event. Credence is given to this possi-
bility because LPA (likewise for TGFbeta
and EGF), when administered to hOBs,
in isolation, stimulates a small increase
in ALP (Blackburn and Mansell, 2012).
In accordance to the remarks of van de
Peppel and van Leeuwen research could
now extend to identifying the signaling
networks that exist for LPA and 1,25D in
hOBs whether they are related directly to
hOB fate or to other cell types within the
bone microenvironment.
The discovery of signaling co-operation
between LPA and 1,25D in the regulation
of ALP is an important development given
the vital role of this enzyme in bonematrix
calcification (Whyte, 2010). Importantly
our findings echo an earlier, very signif-
icant event in our understanding of sig-
nal transduction “cross-coupling” wherein
a promitogenic stimulus (e.g., LPA) con-
verges with a pro-differentiating steroid
hormone (e.g., 1,25D) response (Schule
and Evans, 1991). Identifying LPA as a
molecule with the capacity to enhance
1,25D-induced ALP adds another interest-
ing layer that may extend to the processes
of bone repair and regeneration; LPA is a
product of platelet activation and a rec-
ognized mediator of soft tissue healing
(Moolenaar et al., 2004). There is poten-
tial therefore to consider LPA and related
molecules in a bone regenerative context,
either in a controlled release format or
as coatings to contemporary metal and
ceramic devices.
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